HILLSBOROUGH,Eno Research and Development, a contract research organization based in RTP, has won a contract to study assays related to multiple sclerosis (MS).
Eno River will work with Nutra Pharma Corp. of Boynton Beach, FL, on the project. Nutra Pharma holds several patents related to development of drugs for treatment of HIV and MS.
Financial terms were not disclosed.
The RTP firm was retained to study RPI-78M in pre-clinical assays as a possible MS treatment.
“Much effort has gone into identifying genes that cause or contribute to the disease process of MS,” added James Flowers, president and chief scientific officer of the CRO, in a statement. “Still, it is unknown how many of these genes actually relate to the pathogenesis of this disease. RPI-78M may allow us to better elucidate the underlying mechanisms of MS while evaluating its potential therapeutic benefits.”
The research will continue through the rest of the year.
